B Cell Lymphoma Clinical Trial
Official title:
The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
This is a clinical study to observe the safety and feasibility of chimeric antigen receptor 19 (CART-19) cells in relapsed and refractory patients with CD19+ B cell lymphoma.
This is a study for the patients with B cell lymphoma. Subjects will be staged and the
suitability of their T cells for CART-19 manufacturing will be determined at entry phase.
Subjects will be collected their T cells and modify them, the modification is a genetic
change, that CD19:4-1BB:CD3 modified T cells, in order to tells the T cells to recognize
their target tumor cells and potentially kill them, but not other normal cells in the
subject's body. The CART cells will then be expanded in vitro and then administered to
subjects.
The purpose of this study is to assess ssess the safety and feasibility of CART-19 cells in
the patients with relapsed and refractory CD19+ B cell lymphoma.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
| Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Withdrawn |
NCT02547948 -
CD19-targeting CAR T Cells for B Cell Lymphoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03258047 -
Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT03478514 -
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
|
Phase 2 | |
| Not yet recruiting |
NCT06058858 -
Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
|
||
| Recruiting |
NCT06415708 -
Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT03307746 -
A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT03670888 -
A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients
|
Phase 1 | |
| Recruiting |
NCT06131801 -
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
|
||
| Recruiting |
NCT06213311 -
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT04008251 -
Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT04637763 -
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
|
Phase 1 | |
| Recruiting |
NCT04782193 -
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03146533 -
CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05385263 -
Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion
|
Phase 2 | |
| Recruiting |
NCT03366324 -
Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03929107 -
Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.
|
Phase 2 | |
| Enrolling by invitation |
NCT05332054 -
Long-Term Follow-up Study
|
||
| Recruiting |
NCT04289220 -
Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia
|
Phase 1 |